ARTICLE | Deals
With biliary readout looming, Jazz-Zymeworks deal could grow much larger
Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout
October 19, 2022 9:44 PM UTC
A deal that gives Jazz rights to Zymeworks’ HER2-targeting bispecific for multiple cancers will strengthen the Canadian biotech’s balance sheet as it advances its oncology pipeline, but Jazz is waiting for a key clinical readout before making a larger financial commitment.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is paying $50 million up front for most global rights to zanidatamab (ZW25), with an option to pay Zymeworks Inc. (NASDAQ:ZYME) another $325 million pending results from the pivotal Phase IIb HERIZON-BTC-01 trial to treat biliary tract cancer...